August 28, 2018
HOUSTON–(BUSINESS WIRE)–SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts, today announced issuance of U.S. Patent No. 10,052,410, “Methods and Compositions For Repair Of Cartilage Using An In Vivo Bioreactor.”
The technology described in the patent involves an in vivobioreactor which acts as a delivery system to feed and grow cells, like fibroblasts, and induces cellular differentiation. Additionally, the device will also be subject to one or more growth factors which may enhance differentiation of the cells.
“Our patent portfolio uniquely positions us at the forefront of human dermal fibroblast cell therapy for spinal disc regeneration,” said Pete O’Heeron, Chief Executive Officer, SpinalCyte. “As leaders in this field, we continue to expand our intellectual property protections.”
With this addition, SpinalCyte’s portfolio now includes 33 U.S. and foreign patents issued and 43 patents pending.
Based in Houston, Texas, SpinalCyte, LLC is a regenerative medicine company developing an innovative solution for spinal disc regeneration using human dermal fibroblasts. Currently, SpinalCyte holds 33 U.S. and international issued patents and has filed for an additional 43 patents pending. Funded entirely by angel investors, SpinalCyte represents the next generation of medical advancement in cell therapy. Visit www.spinalcyte.com.